Stopping & switching

Do You Have to Take Wegovy Forever?

The label sets no stop date and obesity societies now strongly recommend continuing during maintenance - but two 2026 trials changed the question from whether to stop to whether you can use less.

Last verified September 14, 2026·16 sources cited·Wegovy Zepbound

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Nobody prescribing Wegovy will hand you a calendar with an end date on it. There isn’t one on the label, and there isn’t one in the guidelines.

That is not evasion. It reflects how the medical world now classifies obesity - as a chronic condition managed the way high blood pressure or high cholesterol is managed, where the treatment works while you take it and stops working when you don’t. Whether that framing feels right to you is a personal question. What the evidence actually says is a factual one, and it is worth separating them.

This article covers Wegovy specifically but applies broadly to the class: Ozempic and Rybelsus (also semaglutide), Zepbound and Mounjaro (tirzepatide), and the newer oral options. Where it describes doses, escalation or missed doses, it is summarizing the FDA-approved prescribing information and Instructions for Use - not instructing you. None of this is medical advice. Decisions about starting, continuing, changing or stopping belong with the healthcare provider who prescribed the drug, and you should follow your own prescription.

What does the label actually say about duration?

The Wegovy prescribing information, revised June 2026, sets out a starting dose of 0.25 mg once weekly, an escalation schedule that steps up every four weeks (0.5 mg, then 1 mg, then 1.7 mg), and a maintenance dosage from week 17 onward [1].

What it does not include is a stop date, a maximum duration, or a re-evaluation trigger. The indication itself is worded to include maintenance: Wegovy is indicated “to reduce excess body weight and maintain weight reduction long term” in adults with obesity or overweight with at least one weight-related condition [1].

The Zepbound label uses nearly identical language for tirzepatide - “to reduce excess body weight and maintain weight reduction long term” [2]. The phrase “long term” is doing real work in both.

What do the professional bodies say?

In April 2026, three organizations - The Obesity Society, the Obesity Medicine Association and the Obesity Action Coalition - published a joint expert guidance statement in the journal Obesity, built with the GRADE method that formal guidelines use to grade evidence quality and recommendation strength.

The panel made strong recommendations for semaglutide and tirzepatide based on moderate-certainty evidence. And, directly to this question, continuing obesity medications during weight maintenance received a strong recommendation [3].

Their framing throughout: obesity is “a chronic, often progressive, disease requiring comprehensive, long-term, and person-centered care” [3].

Why do they say that? The withdrawal trials

Because the trials designed to answer this question all pointed the same direction.

STEP 4 took people who had already titrated to Wegovy 2.4 mg and randomized them to continue or to switch to placebo, keeping lifestyle support in both groups. Over the following 48 weeks, the continuers lost a further 7.9% of body weight while the placebo group gained 6.9% - a difference of 14.8 percentage points. Waist circumference, blood pressure and physical-functioning scores moved in opposite directions too [4].

SURMOUNT-4 did the same thing with tirzepatide. After 36 weeks at the maximum tolerated dose, participants had lost 20.9%. Randomized to continue or stop, the continuers lost another 5.5% over a year while those switched to placebo regained 14.0%. Nearly 90% of continuers held at least 80% of their loss; 16.6% of the placebo group did [5].

Pooling everything, a 2026 meta-regression of six randomized trials found that 60% of the weight lost is regained within a year of stopping, with a projected plateau around 75% [6].

How long has anyone actually taken it?

This is the honest limit of the evidence. “Forever” has not been studied, because the drug has not been available that long.

The longest randomized exposure to semaglutide 2.4 mg is the SELECT trial. It enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, with a mean 34.2 months on drug and 39.8 months of follow-up [7]. Weight loss continued for about 65 weeks and then held: at week 208, mean weight was down 10.2% versus 1.5% on placebo, with waist circumference down 7.7 cm versus 1.3 cm [8].

The longest dedicated weight-management trial is STEP 5, which ran 104 weeks in 304 adults. Mean weight change at two years was -15.2% versus -2.6% on placebo, and 77.1% versus 34.4% achieved at least 5% loss [9].

So: four years of randomized safety and efficacy data for semaglutide 2.4 mg, two years for the weight-management indication specifically. Beyond that, the record is observational.

Is long-term use safe?

SELECT is the best answer available, because it followed a large, diverse population for nearly four years with safety as an explicit focus.

The headline finding runs against expectations: serious adverse events were less frequent with semaglutide than with placebo - 33.4% versus 36.4% - driven mainly by fewer cardiac events and fewer infections [7]. That pattern held across every BMI category studied.

What was more frequent was stopping. Adverse events leading to permanent discontinuation occurred in 16.6% of the semaglutide group versus 8.2% of the placebo group, driven by gastrointestinal events (10.0% versus 2.0%) [7]. A dedicated safety analysis published in Obesity in 2025 added detail: discontinuations happened mostly during the 16-week dose escalation, and the proportion who stopped because of a serious adverse event was similar between groups (3.6% versus 4.1%) [10]. Gallbladder-related disorders were somewhat more common with semaglutide (2.8% versus 2.3%).

No increased rates of acute pancreatitis, malignant neoplasms, acute kidney failure, or suicidal ideation and behavior were seen [10]. Suicide and self-injury serious adverse events were identical between groups at 0.11%.

One important caveat the authors flag themselves: SELECT excluded people with chronic pancreatitis, recent malignancy and severe psychiatric disorders, so those findings do not generalize to those groups [10].

Is the real question “stop or continue” - or “how much”?

For most of this drug’s history, the only two options discussed were staying on the full dose or stopping. Two trials published in 2026 added a third.

SURMOUNT-MAINTAIN is the first randomized test of lowering the dose for maintenance. Across 20 US sites, 441 adults took tirzepatide at the maximum tolerated dose for 60 weeks; 378 were then randomized to continue at that dose, drop to 5 mg, or switch to placebo for 52 weeks. At week 112:

Group	Weight change from baseline
Maximum tolerated dose	-21.9%
Tirzepatide 5 mg	-16.6%
Placebo	-9.9%

Rescue tirzepatide was needed by 8% of the maximum-dose group, 25% of the 5 mg group and 67% of the placebo group [11]. The authors’ own conclusion: reducing to 5 mg “might provide a valuable alternative to discontinuation, although individuals’ treatment response might vary.”

ATTAIN-MAINTAIN tested a different kind of step-down: switching from an injection to a daily pill. It randomized people who had finished the SURMOUNT-5 trial on injectable tirzepatide or injectable semaglutide to once-daily oral orforglipron or placebo for 52 weeks. Participants who had reached a weight plateau kept 74.7% of their weight reduction on orforglipron versus 49.2% on placebo (the tirzepatide cohort) and 79.3% versus 37.6% (the semaglutide cohort) [12]. There was no arm that continued the original injection, so this does not show orforglipron is as good as staying put - only that it beats stopping.

A 2026 commentary in Diabetes, Obesity and Metabolism argues these results justify borrowing the induction-and-maintenance framing from other fields of medicine: a more intensive phase to lose the weight, then a possibly less intensive regimen to hold it [13]. A broader framework published in Obesity Pillars in 2026 goes further, arguing that care after incretin-induced weight loss should move “beyond a binary choice between indefinite maximum-dose obesity medication and treatment discontinuation,” and naming five strategies that need study: staying on drug, monitored dose reduction with pre-agreed criteria for going back up, switching to an oral agent, reduced-frequency dosing, and intermittent rescue treatment [27].

That is a framing to watch, not a protocol. No guideline has adopted it, and a separate 2026 expert-perspectives paper in Obesity still describes pharmacotherapy as lifelong once initiated - a position stated as expert opinion rather than graded evidence [28].

For Wegovy specifically, the label already allows a lower option: the maintenance dosage for weight reduction in adults is “either 1.7 mg or 2.4 mg (recommended),” and prescribers are told to consider treatment response and tolerability when choosing [1]. That is a labeled conversation you can have.

What does staying on it cost?

For a lot of people this, not the science, is what decides the question.

As of September 2026, Novo Nordisk’s standard self-pay price for Wegovy pens is $349 per month, with $399 per month for the 7.2 mg high dose, and a $199 introductory price for the first two fills of the 0.25 mg or 0.5 mg starter doses running through December 31, 2026 [14]. That is $4,188 for a year at the standard price, or a little over $20,000 across five years before any dose changes.

Other routes as of September 2026:

Wegovy tablets: $149 per month for 1.5 mg, $199 for 4 mg, $299 for 9 mg and 25 mg [14].
Subscription plans through telehealth partners, launched March 31, 2026: $329 per month on a 3-month plan, $299 on 6 months, $249 on 12 months for pens [15].
Medicare GLP-1 Bridge: a flat $50 monthly copay for eligible Part D beneficiaries, covering all formulations of Wegovy and Foundayo plus the Zepbound KwikPen, running through December 31, 2027 [16].
List price change: Novo announced on February 24, 2026 that effective January 1, 2027 it will cut the wholesale acquisition cost of Wegovy injection 2.4 mg and Wegovy tablets 25 mg, Ozempic 0.5/1/2 mg and Rybelsus to $675 per month - roughly a 50% cut for Wegovy and 35% for Ozempic - while saying self-pay and direct-to-patient prices are unaffected [17]. List price mainly matters to people whose cost sharing is a percentage of list rather than a flat copay.

One detail that catches people out: manufacturers and the federal TrumpRx site all state that money spent through a self-pay offer does not count toward your deductible or out-of-pocket maximum, and cannot be submitted for reimbursement [18].

For a rounder picture of pricing, coverage and savings programs, see this site’s access and pricing coverage, which tracks it in far more detail than this article does.

What if my insurance changes mid-treatment?

It is a common enough problem to have a standard shape.

The largest example: effective July 1, 2025, CVS Caremark removed Zepbound from its biggest commercial template formularies and made Wegovy the preferred weight-management GLP-1, affecting roughly a third of the people it covers [19]. After the switch, more than 95% of prescriptions filled by affected members were for Wegovy, versus a roughly even split before. Existing Zepbound prior authorizations were transitioned to Wegovy so members did not have to repeat the process, and a formulary exception process was available for people who had already tried Wegovy and had severe or intolerable side effects or insufficient weight loss [19]. That decision has since been partly reversed. CVS Health announced on May 28, 2026 that Caremark will add Zepbound back to its most common commercial formularies “as an additional preferred option” effective October 1, 2026 - a date still ahead as of this writing - for plan sponsors that elect to cover these medications, while Wegovy injection and pill retain preferred status. CVS did not publish tier placement or copay amounts, which individual plan sponsors set [20].

What to know if something similar happens to you:

Roughly 90% of employers that cover GLP-1s for obesity require prior authorization, and 48% set BMI or comorbidity thresholds beyond the FDA label [21].
Most plans allow at least 180 days to file an internal appeal, and after internal appeals are exhausted you generally have a right to external review by an independent reviewer [21].
The CMS Interoperability and Prior Authorization Final Rule takes effect in 2026 with 72-hour urgent and 7-day standard decision deadlines, and requires insurers to give specific denial reasons [21].
A coverage change is a reason to talk to a prescriber before your supply runs out, not after. Manufacturer self-pay channels can bridge a gap while an appeal runs.

How many people actually stay on it?

Fewer than the trials would suggest, though the number is improving.

A Danish national cohort published in August 2026 followed all 77,310 adults without diabetes who started semaglutide for weight loss: 18% had stopped by three months and 52% by one year, with the highest dropout among adults aged 18 to 30 [22].

In the US, a claims analysis of 33,607 commercially insured members without diabetes found one-year persistence rising from 33.2% among 2021 starters to 60.9% among those starting in the first half of 2024. Tirzepatide ran 64.0% and 64.8% in 2023 and early 2024 [23]. The authors credit the end of shortages, better dose escalation and side-effect management, and lifestyle program support.

What if I want to stop anyway?

People do, for reasons that are perfectly reasonable: cost, side effects, wanting to know whether they can hold it, or simply not wanting to inject something weekly for decades.

Oprah Winfrey described exactly that experiment publicly at the end of 2025. She told People she quit about six months in to see whether she could hold the loss on her own, regained roughly 20 pounds over 12 months, restarted, and concluded the drugs are “going to be a lifetime thing” [24]. A single anecdote is not evidence, but it is the version of this story most people have heard.

If you are thinking about it, a few things the evidence supports bringing to the conversation:

There is no tested taper yet. Every completed withdrawal trial stopped the drug outright. A 2026 review states that whether structured tapering helps is unknown and needs prospective study [25]. The REST trial, which began recruiting in Toronto in 2026, is the first randomized study built to compare gradual dose reduction with abrupt stopping; it is scheduled to run to 2029 [29].
A lower approved maintenance dose exists for both Wegovy (1.7 mg) and Zepbound (5 mg or 10 mg instead of 15 mg), and both labels tell prescribers to consider a lower maintenance dosage for tolerability [1][2].
Restarting after a gap is not automatic. The current Wegovy label says that if two or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce gastrointestinal side effects [1].
Exercise is the one thing with randomized support for holding weight after treatment ends, from the Danish S-LiTE trial, where people who had combined supervised exercise with a GLP-1 held their loss far better a year after everything stopped than those who had used the drug alone [26].

So: forever?

Here is the accurate answer. The label sets no end date. Obesity societies strongly recommend continuing during maintenance. The withdrawal trials show that most of the benefit goes when the drug goes. Four years of randomized safety data exist and look reassuring. And as of 2026, “continue” no longer has to mean “continue at the top dose forever” - two randomized trials have now shown that lower-intensity maintenance holds a meaningful share of the loss.

What nobody can tell you is what happens at year ten, because nobody has looked. That is worth knowing, and it is worth discussing with your prescriber alongside everything else.

Sources

Questions people ask

Does the Wegovy label say how long to take it?

No. The Wegovy prescribing information describes a starting dose, an escalation schedule and maintenance dosages, but sets no stop date. The indication itself is worded as reducing excess body weight and maintaining weight reduction long term.

What do doctors' groups recommend?

In April 2026, The Obesity Society, the Obesity Medicine Association and the Obesity Action Coalition published joint GRADE-based guidance that gave a strong recommendation to continuing obesity medications during weight maintenance.

How long has anyone actually taken it in a trial?

The longest randomized exposure to semaglutide 2.4 mg is the SELECT cardiovascular trial, with a mean of about 34 months on drug and 40 months of follow-up. The longest dedicated weight-management trial is STEP 5 at 104 weeks.

Is long-term use safe?

In SELECT, serious adverse events were less frequent with semaglutide than placebo (33.4% versus 36.4%), and there was no increase in pancreatitis, cancer, acute kidney failure or suicidal ideation and behavior. More people stopped for adverse events on semaglutide (16.6% versus 8.2%), mostly gastrointestinal and mostly during the 16-week escalation.

Can I stay on a lower dose instead?

The Wegovy label lists 1.7 mg or 2.4 mg as maintenance dosages for weight reduction in adults, so a lower approved maintenance dose already exists. For tirzepatide, the SURMOUNT-MAINTAIN trial tested dropping to 5 mg and found it held more weight loss than placebo but less than staying at the maximum tolerated dose. Dose decisions belong with a prescriber.

What does it cost to stay on it for years?

As of September 2026, Novo Nordisk's standard self-pay price for Wegovy pens is $349 per month, or $4,188 a year. Subscription plans through telehealth partners run $249 to $329 per month. Wegovy tablets run $149 to $299 per month by dose. Insurance coverage varies enormously.

What if my insurance drops coverage?

That happens often enough to have a playbook. Most plans have a formulary exception process, most allow at least 180 days to file an internal appeal, and after internal appeals you generally have a right to external review. Manufacturer self-pay channels also exist as a bridge.

Is stopping ever the right call?

There are clear situations where a healthcare provider will stop or pause it - planning a pregnancy, for example, since the label says to discontinue at least two months beforehand. Beyond that, it is an individual decision made with a prescriber, weighing what the withdrawal trials show against cost, side effects and personal goals.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.